Researchers have developed a novel digital cognitive testing platform, using the Oxford Cognitive Testing Portal, that correlates with serological biomarkers to accurately measure cognitive impairment in Alzheimer's patients. The study highlights the platform's effectiveness in capturing subtle signs of impairment, potentially revolutionizing early diagnosis and tracking of Alzheimer's disease.